Pregledni rad

Corneal collagen crosslinking: from basic research to clinical application

ADRIAN LUKENDA ; Department of Ophthalmology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia
JOSIP PAVAN ; Department of Ophthalmology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia
SNJEŽANA KAŠTELAN ; Department of Ophthalmology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia
MARKO ]URKOVIĆ ; Department of Ophthalmology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia

Sažetak

Corneal collagen crosslinking is a promising new treatment of progressive corneal ectasia. Its clinical use has been rapidly increasing since it was originally introduced in 1997 as the first treatment that can improve biomechanical stability of theweakened cornea. The method is based on the combined action of photosensitizer riboflavin (vitamin B2) and ultraviolet A light, which induce the formation of new covalent bonds between the collagen
fibers.

Our systematic search of literature in English has yielded only eight prospective trials with the efficiency and safety data published to date. However, all of the published studies reveal a halt in the progression or a slight improvement of corneal ectasia with the low complication and failure rates after the treatment. In this review we are highlighting the method’s history, scientific basis and its current clinical application in order to provide clinicians with the recent data on its benefits and potential risks.

Ključne riječi

collagen; crosslinking; cornea; ectasia; keratoconus; riboflavin; ultraviolet; review

Hrčak ID:

52678

URI

https://hrcak.srce.hr/52678

Datum izdavanja:

31.3.2010.

Posjeta: 1.356 *